Insider Transaction Report for Acrivon Therapeutics, Inc.

This filing details a Form 4 filed by Michaela Levin, Chief Business Officer of Acrivon Therapeutics, Inc. On August 31, 2026, Levin acquired 30,000 shares of Common Stock and a stock option to purchase 130,000 shares of Common Stock, both with a transaction price of $0.00. The restricted stock units (RSUs) acquired are subject to full vesting on September 1, 2027, contingent upon continuous service. The stock option vests 25% on September 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also contingent upon continuous service. The option has an exercise price of $2.09 and an expiration date of August 30, 2036. All transactions are reported as direct ownership.